Menu

Hot Flashes 0302

Study Closed

Type of Study:

Hot Flashes Moderate to Severe

Title of Study:

Hot Flashes 0302

Short Title:

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause

Study Length: This study will consist of a screening period and a 52 week treatment period. Safety follow up will occur 3 weeks after the last dose of study drug.

Target Age/Sex: 40 Years to 65 Years , Female

Benefits:

Participants will receive at no cost: Study medication and study related procedures. Subject may also receive a stipend for time/travel related to the study.

Link: ClinicalTrials.gov